Biosimilar Drugs Market - a Cost-Saving Option to Expensive Biologics: Overview of How Much Have CMOs Benefited from Biosimilars
Biosimilars are drugs that are highly similar but not identical to branded innovator biologics: large molecule, immunogenic drugs produced from living cells. Innovator biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded drugs and their generics.
View full press release